| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Report Date |
|---|---|---|---|---|---|
| Innoviva, Inc. | 10%+ Owner | $162,821,214 | 08 Jul 2022 | ||
| Michael Gutch | Chief Financial Officer and Chief Business Officer | 18 Jan 2022 | |||
| David C. Hastings | Director | 07 Jul 2022 | |||
| Anna Diaz Triola | Chief Commercial Officer | 11 Jul 2022 | |||
| Matthew Ronsheim | Chief of Pharma Sciences & MFG | 07 Jul 2022 | |||
| Ruben Tommasi | Chief Scientific Officer | 07 Jul 2022 | |||
| Manoussos Perros | President and CEO, Director | 07 Jul 2022 | |||
| Kristie Ann Wagner | VP, Principal Fin & Acct Off | 11 Jul 2022 | |||
| David D. Meek | Director | 07 Jul 2022 | |||
| Elizabeth M. Keiley | General Counsel | 07 Jul 2022 | |||
| Howard Mayer | Director | 07 Jul 2022 | |||
| David Altarac | Chief Medical Officer | 07 Jul 2022 | |||
| John Patrick Mueller | Chief Development Officer | 07 Jul 2022 | |||
| Heather A. Berger | Director | 07 Jul 2022 |
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| No insider transactions were found in the last 12 months for this issuer. | ||||||||||